Expression and clinical significance of girdin in gastric cancer
- Authors:
- Published online on: February 24, 2014 https://doi.org/10.3892/mco.2014.265
- Pages: 425-428
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Gastric cancer is one of the most common malignant tumors and the second leading cause of cancer‑related mortality. Elucidating the molecular mechanism underlying the development of gastric cancer is crucial in identifying gastric cancer‑susceptible populations, screening for tumor markers and in the application of gene therapy. This study was conducted to investigate girdin expression in gastric cancer and para‑cancer tissues and to elucidate the role of girdin in the development of gastric cancer. Tissue microarray and streptavidin‑peroxidase immunohistochemical staining were used to detect girdin expression in 105 gastric cancer and 72 para‑cancer tissue samples. Analyses of the patients' clinical and pathological data were also performed. The expression ratio of girdin was 40.0% in gastric cancer and 11.1% in the para‑cancer tissues and the difference was statistically significant (P<0.05). Girdin expression was found to be positively correlated (P<0.05) with tumor invasion depth and lymph node metastasis, while no significant associations were found between girdin expression and gender, age, tumor size, pathological grade and clinical stage (P>0.05). In conclusion, the upregulation of girdin expression in gastric cancer may contribute to tumor metastasis and cancer development, suggesting that girdin may be a novel indicator for evaluating lymph node metastasis and gastric cancer outcome.
